Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACH-1095
- Development stage
- Discontinued
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ACH-1095 is a small molecule direct-acting antiviral (DAA) that targets the non-structural protein 5A (NS5A) of the hepatitis C virus (HCV). NS5A is a multifunctional phosphoprotein essential for the formation of the viral replication complex and the assembly of new infectious virus particles. Initially developed by Achillion Pharmaceuticals and later licensed to Gilead Sciences (where it was designated GS-9525), ACH-1095 was designed to provide potent, pan-genotypic inhibition of HCV replication. However, clinical development was discontinued as the therapeutic landscape for hepatitis C evolved toward highly effective, short-course combination regimens like sofosbuvir-based therapies, rendering earlier-generation single-agent candidates less competitive.
- Other names
- CAS 1207451-77-1CAS1207451-77-1CAS-1207451-77-1
02
Targets
NS5A (Hepatitis C virus nonstructural protein 5A (genotype 1b))
Beyond the preview
Go deeper on ACH-1095.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACH-1095.